Drug Trial Radar · NCT03052010
The Partners Scale-Up Project
Last checked: Nov 19, 2026Latest source record: Oct 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,898
Actual
Start
Feb 6, 2017
Primary completion
Dec 15, 2020
Study completion Apr 30, 2021
Sponsor
- Lead sponsor
- University of WashingtonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kenya Medical Research Institute; Kenya National AIDS & STI Control Programme; National Institute of Mental Health (NIMH); Bill and Melinda Gates Foundation
- First posted
- Feb 14, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
An implementation project to scale-up delivery of antiretroviral-based HIV-1 prevention methods to Kenyan HIV-1 serodiscordant couples in HIV-1 care centers. Pre-exposure prophylaxis (PrEP) as a bridge to antiretroviral therapy (ART) HIV-1 prevention strategy will be introduced into 24 public HIV-1 care centers in central and western Kenya according to national guidelines using a stepped wedge design, stratified by region.
Conditions
- HIV-1-infection
Interventions
Integrated PrEP as a bridge to ART HIV-1 prevention strategyOther
The PrEP as a bridge to ART intervention will be introduced into clinics according to Kenya national guidelines using a stepped wedge design, stratified by region. The components of the intervention are: a) Couples' HIV-1 counseling and testing; 2) PrEP as a bridge to ART: PrEP offered prior to ART initiation in couples in which the HIV-1 infected partner is not on ART due to refusal/delay, during the first 6 months after ART start during viral decline, and then discontinuation; 3) ART at any CD4 count, offered to all HIV-1 infected partners, with ongoing promotion/counseling for those delaying/declining;4) Standard of care HIV-1 prevention services
PrEPDrug
A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
ARTDrug
ART medications will be provided according to Kenya national ART policies and will come from clinic stocks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of HIV-1 infected persons whose partners are tested for HIV-1 before/after PrEP as a bridge to ART is implementedTime frame: up to 36 months
- PrEP initiationTime frame: up to 36 months
- PrEP adherenceTime frame: up to 6 months
- HIV-1 uninfected partners staying HIV-1 uninfected.Time frame: up to 36 months
- ART initiationTime frame: up to 36 months
- ART adherenceTime frame: up to 6 months
- Facilitators and barriers to implementation of integrated PrEP and ARTTime frame: up to 36 months
- PrEP delivery operational toolsTime frame: 24 months
- Cost and cost-effectiveness of the integrated PrEP and ART when delivered in public health clinics.Time frame: up to 36 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
KEMRI
Kisumu, Kenya
Partners in Health Research and Development
Thika, Kenya
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.